ASP1951 + pembrolizumab

ASP1951 + pembrolizumab is a combination regimen comprised of ASP1951, a monoclonal antibody that functions as a GITR agonist, and pembrolizumab, a monoclonal antibody checkpoint inhibitor that targets PD-1. This combination is investigated for the treatment of advanced solid tumors including locally advanced or metastatic malignancies such as squamous cell carcinoma of the head and neck, non-small cell lung cancer (all PD-L1 status and PD-L1 high), and cervical cancer. The aim of combining a GITR agonist with a PD-1 inhibitor is to enhance anti-tumor immune response by simultaneously activating effector T cells and relieving immune checkpoint suppression. ASP1951 is developed and sponsored by Astellas Pharma, while pembrolizumab is marketed as KEYTRUDA by Merck. The main development focus is on improving tolerability, safety, pharmacokinetics, and establishing the recommended Phase 2 dose and maximum tolerated dose for the combination in patients with advanced solid tumors[1][2][3].

Brand names

Keytruda

Other names

ASP-1951ASP1951ASP 1951pembrolizumabMK-3475MK3475MK 3475